Patents by Inventor Jaume Adan

Jaume Adan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered anti-alpha V-integrin hybrid antibodies
    Patent number: 8562986
    Abstract: The invention relates to engineered antibodies which specifically bind to integrin receptors, especially the alpha V integrin receptor subunit. The antibodies comprise the antigen binding sites (CDRs) of a known mouse anti-integrin antibody, as well as hybrid light chain variable sequences, mutated heavy chain variable sequences (Frs) and modified heavy chain constant sequences. The novel antibodies have improved immunogenic and expression properties and elicit excellent anti-angiogenic as well as anti-tumor activities in humans in monotherapy but also and above all in combination with other angiogenesis and tumor inhibiting agents.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: October 22, 2013
    Assignee: Merck Patent GmbH
    Inventors: Simon Goodman, Diane Hahn, Francesc Mitjans, Jaume Adan, Kin-Ming Lo
  • ENGINEERED ANTI-ALPHA V-INTEGRIN HYBRID ANTIBODIES
    Publication number: 20100254977
    Abstract: The invention relates to engineered antibodies which specifically bind to integrin receptors, especially the alpha V integrin receptor subunit. The antibodies comprise the antigen binding sites (CDRs) of a known mouse anti-integrin antibody, as well as hybrid light chain variable sequences, mutated heavy chain variable sequences (Frs) and modified heavy chain constant sequences. The novel antibodies have improved immunogenic and expression properties and elicit excellent anti-angiogenic as well as anti-tumor activities in humans in monotherapy but also and above all in combination with other angiogenesis and tumor inhibiting agents.
    Type: Application
    Filed: July 17, 2008
    Publication date: October 7, 2010
    Applicant: MERCK PATENT GMBH
    Inventors: Simon Goodman, Diane Hahn, Francesc Mitjans, Jaume Adan, Kin-Ming Lo
  • 4-Amino-5-oxo-8-phenyl-5H-pyrido(2,3-D) pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours
    Patent number: 7745434
    Abstract: Compounds of the formula (I), in which R6, R7, R8, R9, Het1, X and X? have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: June 29, 2010
    Assignee: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Karl-August Ackermann, Helene Crassier, Alfred Jonczyk, Wilfried Rautenberg, Gema Tarrason, Elisabet Rosell-Vives, Jaume Adan, Claudia Cases
  • Pyridopyrimidinones
    Patent number: 7547695
    Abstract: The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and X? have the designations cited in patent claim 1. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumors.
    Type: Grant
    Filed: October 14, 2004
    Date of Patent: June 16, 2009
    Assignee: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Helene Crassier, Karl-August Ackermann, Wolfgang Staehle, Alfred Jonczyk, Wilfried Rautenberg, Francesc Mitjans, Elisabet Rosell-Vives, Jaume Adan, Marta Soler Riera
  • 4-Amino-5-Oxo-8-Phenyl-5H-Pyrido(2,3-D) Pyrimidine Derivatives as Tyrosine Kinase and Raf Kinase Inhibitors for the Treatment of Tumours
    Publication number: 20080146560
    Abstract: Compounds of the formula (I), in which R6, R7, R8, R9, Het1, X and X? have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours
    Type: Application
    Filed: October 20, 2005
    Publication date: June 19, 2008
    Inventors: Guenter Hoelzemann, Karl-August Ackermann, Helene Grassier, Alfred Jonczyk, Wilfried Rautenberg, Gema Tarrason, Elisabet Rosell-Vives, Jaume Adan, Claudia Cases
  • Imidazole Derivatives
    Publication number: 20070225347
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X and X? have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: March 15, 2005
    Publication date: September 27, 2007
    Applicant: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Helene Crassier, Alfred Jonczyk, Wolfgang Staehle, Arne Sutter, Wilfried Rautenberg, Francesc Mitjans, Elisabet Rosell-Vives, Jaume Adan, Marta Riera
  • Pyridopyrimidinones
    Publication number: 20070099910
    Abstract: The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and X? have the designations cited in patent claim 1. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumours.
    Type: Application
    Filed: October 14, 2004
    Publication date: May 3, 2007
    Applicant: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Helene Crassier, Karl-August Ackermann, Wolfgang Staehle, Alfred Jonczyk, Wilfried Rautenberg, Francesc Mitjans, Elisabet Rosell-Vives, Jaume Adan, Marta Soler Riera
  • Aminobenzimidazole derivatives
    Publication number: 20070021456
    Abstract: Novel compounds of formula (I) are disclosed, where R1, R1?, L, Y, m and p have the meanings given in claim 1, which are inhibitors of tyrosine kinases, in particular, TIE-2 and Raf kinases and can be used for the treatment of tumors.
    Type: Application
    Filed: July 19, 2004
    Publication date: January 25, 2007
    Applicant: MERCK PATENT GMBH
    Inventors: Francesc Mitjans, Elisabet Rosel-Vives, Jaume Adan, Marta Soler, Guenter Hoelzemann, Helene Crassier, Karl-August Ackermann, Wolfgang Staehle, Alfred Jonczyk, Wilfried Rautenberg
  • Urea derivatives and their use as tyrosinkinase inhibitors
    Publication number: 20060241301
    Abstract: The invention relates to novel urea derivatives which inhibit tyrosinkinases, especially TIE-2, and Raf kinases and which are used in the treatment of tumors.
    Type: Application
    Filed: July 2, 2004
    Publication date: October 26, 2006
    Inventors: Gunter Hoelzemann, Karl-August Ackermann, Wolfgang Staehle, Alfred Jonczyk, Wilfried Rautenberg, Helerie Crassier, Francesc Mitjans, Elisabet Rosell-Vives, Jaume Adan, Marta Soler Riera
  • Anti-.alpha.V-integrin monoclonal antibody
    Patent number: 5985278
    Abstract: The invention relates to a novel monoclonal antibody, a hybridoma cell line producing said antibody, DNA sequences coding for said antibody, and amino acid sequences. The monoclonal antibody, a preferred embodiment of which is named 17E6, has the following properties:reacting only with the .alpha.V-chain of human .alpha.V-integrins,blocking the attachment to the integrin substrate of the .alpha.V-integrin bearing cell,triggering reversal of established cell matrix interaction caused by .alpha.V-integrins,blocking tumor development, andshowing no cytotoxic activity.
    Type: Grant
    Filed: December 19, 1995
    Date of Patent: November 16, 1999
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Francesc Mitjans, Jaume Piulats, Elisabet Rosell, Jaume Adan, Simon Goodman, Diane Hahn
  • Anti-idiotypic antibodies which induce an immune response against epidermal growth factor receptor
    Patent number: 5969107
    Abstract: The present invention relates to anti-idiotypic antibodies which induce an immune response against tumors, bearing as antigen the epidermal growth factor receptor (EGFR). The antibodies of the invention may mimic said antigen. As preferred embodiment the antibodies of the invention derive from mAB 425 (ATCC HB 9629) or a humanized or chimeric derivative thereof.
    Type: Grant
    Filed: May 24, 1996
    Date of Patent: October 19, 1999
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Ana Carceller, Elisabet Rosell, Alicia Gomez, Jaume Adan, Jaume Piulats
  • Anti-EGFR single-chain Fvs and anti-EGFR antibodies
    Patent number: 5844093
    Abstract: This invention relates to new anti-EGFR antibodies and single-chain Fvs (scFvs) thereof which can be obtained from phage-antibody libraries constructed from cells of an immunized mammalian, preferably a mouse. Two of the single-chain Fvs isolated from the phage-antibody libraries were engineered to create partially humanized whole antibody molecules. These chimeric anti-EGFR antibodies contain constant regions of human immunoglobulins, and can be used as well as the single-chain Fvs as agents for the diagnosis and therapy of human tumors.
    Type: Grant
    Filed: November 17, 1995
    Date of Patent: December 1, 1998
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: A. Cathrine Kettleborough, Mary M. Bendig, Keith H. Ansell, Detlef Gussow, Jaume Adan, Francesc Mitjans, Elisabet Rosell, Francesc Blasco, Jaume Piulats